AP NEWS

Predictive Diagnostics Launches Endometriosis Risk Test

October 4, 2018

SALT LAKE CITY, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC/PINK: PRED), a leader in the use of data analytics for disease identification enabling revolutionary therapeutic approaches, announces that its subsidiary, Predictive Diagnostics, will launch a unique endometriosis risk test this weekend at the 74th American Society of Reproductive Medicine (ASRM) Scientific Congress & Expo in Denver, Colorado.

The test, ARTguide™, is a first-in-class non-invasive diagnostic test for endometriosis and other genetic causes of infertility. ARTguide™ is indicated for the hundreds of thousands of women considering use of Assisted Reproductive Technologies (ART) such as In Vitro Fertilization (commonly referred to as IVF). Next generation sequencers will be used to test the patient for variants in 11 genes known to impact human fertility. Additionally, over 750 DNA markers associated with endometriosis are tested using a proprietary algorithm. The test was developed using tens of thousands of patient samples and billions of analyzed genotypes.

“I am confident that the ARTguide™ test will help couples challenged with infertility to have healthy babies transforming the lucrative assisted reproductive technology market,” said Bradley Robinson, CEO of Predictive Technology Group. “ARTguide™ will provide ‘must-have’ information for couples and their physicians selecting an optimal course of care.”

Predictive Diagnostics was recently created through strategic acquisitions and will process ARTguide™ in its recently acquired CLIA laboratory in Salt Lake City, Utah. Predictive Diagnostics will launch ARTguide™, in six beta sites over the next few months, and the test will be made available to the entire US infertility market in the second quarter of 2019.

About Endometriosis:Approximately 27 million women in the United States are symptomatic of endometriosis. Endometriosis occurs when the tissue similar to the lining of the uterus (womb) is found in other parts of the body, most commonly in the pelvis. Monthly bleeding and inflammation caused by these lesions may severely impact a woman’s quality of life. Some affected women experience severe pain, others infertility, others problems with their periods, and some have no symptoms at all. Today, definitive diagnosis requires surgery. Due to the difficulties, invasiveness, and expense of diagnosing the condition, the majority of women diagnosed with endometriosis suffer for over a decade before receiving treatment. Treatment may involve hormonal suppression or a targeted destruction of the abnormal tissue during surgery.

About Predictive Technology Group, Inc. Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com and Predictivebiotech.com.

Forward-Looking StatementsTo the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Contact:

InvestorsLHA Investor RelationsJody Cain jcain@lhai.com Kevin Mc Cabe kmccabe@lhai.com 310-691-7100

AP RADIO
Update hourly